L.E. Kandalaft

Discipline

Histoire, Philosophie et Sociologie des sciences (2) Sociologie (1) Psychologie (1) Sciences de l'information et de la communication (1) Economies et finances (1)

Type de document

Articles (30) Recensions (9)

Co-auteur

Date

Source

Mot-clé

cancer (20) Cancer (20) Immunotherapy (20) Cancer (20) Immunotherapy (20) Treatment (17) Patients (14) Patients (14) Vaccines (12) Vaccination (12) T cells (12) Vaccination (12) Tumors (11) Tumors (11) Cells (9) thérapie (8) Therapeutics (8) Cancer vaccines (8) Dendritic cells (7) Mice (7) modèle (6) analyse (6) procès (6) survie (6) Development (6) Survival (6) Human beings (6) Lymphocytes (6) Immune response (6) Example (6)

Documents écrit par L.E. Kandalaft (30) | parle de L.E. Kandalaft (0)

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
H. Fritah et al. (21 avr. 2023)
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.
B. Mastelic-Gavillet et al. (2023)
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
B. Gautron Moura et al. (21 déc. 2022)
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
M. Arnaud et al.
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
E.I. Matthaiou et al. (2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
F.G. Herrera et al.
Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.
L.E. Kandalaft et al. (19 nov. 2021)
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
A. Harari et al. (18 nov. 2021)
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
C.L. Chiang et al. (10 sept. 2021)
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
M. Bruand et al. (20 juil. 2021)
Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma.
C. Yakkala et al. (3 juin 2021)
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
J.L. Tanyi et al. (4 mai 2021)
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
J.L. Tanyi et al. (15 mars 2021)
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
P. Baumgaertner et al. (2021)
Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines.
M. Graciotti et al. (2 juin 2020)
Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine.
C. Boudousquié et al. (14 janv. 2020)
Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ.
M. Germann et al. (9 janv. 2020)
Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform.
R. Ahmed et al. (2020)
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
A. Sarivalasis et al. (26 nov. 2019)
Believe in yourself, and enjoy the ride.
L.E. Kandalaft
Rational combinations of immunotherapy with radiotherapy in ovarian cancer.
F.G. Herrera et al.
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
K.F. Bol et al. (18 avr. 2019)
Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.
B. Mastelic-Gavillet et al. (2019)
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
S. Martin Lluesma et al. (23 nov. 2018)
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
S. Bobisse et al. (15 mars 2018)

next